Financial News
Articles published by Cassava Sciences, Inc.

Via GlobeNewswire
Tickers
SAVA

Cassava Sciences Licenses Simufilam Method of Treatment Patent
February 27, 2025
Via GlobeNewswire
Tickers
SAVA


Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
November 25, 2024
Via GlobeNewswire
Tickers
SAVA

Cassava Sciences to Hold Corporate Update on November 25th
November 24, 2024
Via GlobeNewswire
Tickers
SAVA

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
November 18, 2024
Via GlobeNewswire
Tickers
SAVA

Cassava Sciences Reports Q3 2024 Financial and Operating Results
November 07, 2024
Via GlobeNewswire
Tickers
SAVA

Via GlobeNewswire
Tickers
SAVA


Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
September 24, 2024
Via GlobeNewswire
Tickers
SAVA

Cassava Sciences Names Rick Barry as Chief Executive Officer
September 09, 2024
Via GlobeNewswire
Tickers
SAVA

Via GlobeNewswire
Tickers
SAVA

Via GlobeNewswire
Tickers
SAVA

Via GlobeNewswire
Tickers
SAVA


Via GlobeNewswire
Tickers
SAVA


Via GlobeNewswire
Tickers
SAVA


Via GlobeNewswire
Tickers
SAVA

Via GlobeNewswire
Tickers
SAVA



Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
March 04, 2024
Via GlobeNewswire
Tickers
SAVA

Via GlobeNewswire
Tickers
SAVA


Via GlobeNewswire
Tickers
SAVA

Via GlobeNewswire
Tickers
SAVA

Cassava Sciences Appoints Three New Members to its Board of Directors
December 07, 2023
Via GlobeNewswire
Tickers
SAVA

Via GlobeNewswire
Tickers
SAVA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.